{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:43:03Z","timestamp":1788921783287,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Changchun GeneScience Pharmaceutical Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40744-026-00830-9","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:52:59Z","timestamp":1773251579000},"page":"595-610","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of Firsekibart in Treatment of Active Systemic Juvenile Idiopathic Arthritis: A Randomized Phase 2 Study"],"prefix":"10.1007","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct05925452","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Caifeng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junmei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiguo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiping","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuihua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiufen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palasaiti","family":"Adili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"830_CR1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1146\/annurev-med-061813-012806","volume":"66","author":"GS Schulert","year":"2015","unstructured":"Schulert GS, Grom AA. Pathogenesis of macrophage activation syndrome and potential for cytokine-directed therapies. Annu Rev Med. 2015;66:145\u201359.","journal-title":"Annu Rev Med"},{"key":"830_CR2","doi-asserted-by":"publisher","first-page":"1349907","DOI":"10.3389\/fped.2024.1349907","volume":"12","author":"X Zhu","year":"2024","unstructured":"Zhu X, et al. Canakinumab in the treatment of systemic juvenile idiopathic arthritis: a retrospective single-center study in China. Front Pediatr. 2024;12:1349907.","journal-title":"Front Pediatr"},{"issue":"1","key":"830_CR3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12969-024-00974-4","volume":"22","author":"L Qiu","year":"2024","unstructured":"Qiu L, et al. Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis, the first Chinese experience. Pediatr Rheumatol Online J. 2024;22(1):38.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"25","key":"830_CR4","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","volume":"367","author":"N Ruperto","year":"2012","unstructured":"Ruperto N, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2396\u2013406.","journal-title":"N Engl J Med"},{"issue":"11","key":"830_CR5","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1093\/rheumatology\/keh710","volume":"44","author":"AV Ramanan","year":"2005","unstructured":"Ramanan AV, Grom AA. Does systemic-onset juvenile idiopathic arthritis belong under juvenile idiopathic arthritis? Rheumatology (Oxford). 2005;44(11):1350\u20133.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"830_CR6","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jbspin.2013.09.003","volume":"81","author":"S Thierry","year":"2014","unstructured":"Thierry S, et al. Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. Joint Bone Spine. 2014;81(2):112\u20137.","journal-title":"Joint Bone Spine"},{"issue":"2","key":"830_CR7","first-page":"343","volume":"35","author":"EM Behrens","year":"2008","unstructured":"Behrens EM, et al. Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR). J Rheumatol. 2008;35(2):343\u20138.","journal-title":"J Rheumatol"},{"issue":"4","key":"830_CR8","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/art.42037","volume":"74","author":"KB Onel","year":"2022","unstructured":"Onel KB, et al. 2021 American College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2022;74(4):553\u201369.","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"830_CR9","doi-asserted-by":"publisher","first-page":"4611","DOI":"10.1007\/s12325-025-03279-4","volume":"42","author":"H Liu","year":"2025","unstructured":"Liu H, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of Firsekibart, an anti-interleukin-1beta monoclonal antibody, in healthy Chinese participants: a randomized, double-blind, placebo-controlled phase 1 study. Adv Ther. 2025;42(9):4611\u201325.","journal-title":"Adv Ther"},{"issue":"7","key":"830_CR10","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","volume":"40","author":"EH Giannini","year":"1997","unstructured":"Giannini EH, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40(7):1202\u20139.","journal-title":"Arthritis Rheum"},{"key":"830_CR11","first-page":"125","volume":"8","author":"S Grevich","year":"2017","unstructured":"Grevich S, Shenoi S. Update on the management of systemic juvenile idiopathic arthritis and role of IL-1 and IL-6 inhibition. Adolesc Health Med Ther. 2017;8:125\u201335.","journal-title":"Adolesc Health Med Ther"},{"issue":"4","key":"830_CR12","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1093\/rheumatology\/keab619","volume":"61","author":"A De Matteis","year":"2022","unstructured":"De Matteis A, et al. Canakinumab in systemic juvenile idiopathic arthritis: real-world data from a retrospective Italian cohort. Rheumatology (Oxford). 2022;61(4):1621\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"830_CR13","first-page":"194","volume":"42","author":"B Sozeri","year":"2024","unstructured":"Sozeri B, et al. Evaluation of clinical outcomes in systemic juvenile idiopathic arthritis patients treated with biological agents in Turkey: the TURSIS study. Clin Exp Rheumatol. 2024;42(1):194\u2013201.","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"830_CR14","doi-asserted-by":"publisher","first-page":"435","DOI":"10.46497\/ArchRheumatol.2022.8998","volume":"37","author":"F Demir","year":"2022","unstructured":"Demir F, Gurler E, Sozeri B. Efficacy of anakinra treatment in pediatric rheumatic diseases: our single-center experience. Arch Rheumatol. 2022;37(3):435\u201343.","journal-title":"Arch Rheumatol"},{"issue":"12","key":"830_CR15","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s40267-018-0572-5","volume":"34","author":"KA Lyseng-Williamson","year":"2018","unstructured":"Lyseng-Williamson KA. Anakinra in Still\u2019s disease: a profile of its use. Drugs Ther Perspect. 2018;34(12):543\u201353.","journal-title":"Drugs Ther Perspect"},{"key":"830_CR16","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3389\/fphar.2016.00467","volume":"7","author":"G Giancane","year":"2016","unstructured":"Giancane G, et al. IL-1 inhibition in systemic juvenile idiopathic arthritis. Front Pharmacol. 2016;7:467.","journal-title":"Front Pharmacol"},{"issue":"5","key":"830_CR17","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1586\/1744666X.2015.1032257","volume":"11","author":"A Woerner","year":"2015","unstructured":"Woerner A, et al. Complications of systemic juvenile idiopathic arthritis: risk factors and management recommendations. Expert Rev Clin Immunol. 2015;11(5):575\u201388.","journal-title":"Expert Rev Clin Immunol"},{"issue":"11","key":"830_CR18","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1007\/s10067-024-07126-9","volume":"43","author":"C Li","year":"2024","unstructured":"Li C, et al. Efficacy and safety of tocilizumab in Chinese patients with systemic juvenile idiopathic arthritis: a multicentre phase IV trial. Clin Rheumatol. 2024;43(11):3457\u201367.","journal-title":"Clin Rheumatol"},{"issue":"8","key":"830_CR19","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1080\/14740338.2024.2386370","volume":"24","author":"E Kilic Konte","year":"2025","unstructured":"Kilic Konte E, et al. Long-term safety profile and secondary effectiveness of canakinumab in pediatric rheumatic diseases: a single-center experience. Expert Opin Drug Saf. 2025;24(8):915\u201323.","journal-title":"Expert Opin Drug Saf"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00830-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-026-00830-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00830-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T08:46:32Z","timestamp":1779525992000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-026-00830-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["830"],"URL":"https:\/\/doi.org\/10.1007\/s40744-026-00830-9","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"17 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Qian Xu, Xu Zhang, Xianyang Wang, Palasaiti Adili and Wei Qu are employees of Changchun GeneScience Pharmaceutical Co., Ltd. Caifeng Li, Junmei Zhang, Haiguo Yu, Meiping Lu, Sirui Yang, Cuihua Liu, Ping Zeng, Bo Zhao, Xiaoqing Li, Wenjie Zheng, Yue Du, Wei Zhang, Zhihui Li, Xiufen Hu, and Jianming Lai declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, the International Council for Harmonisation (ICH) Guidelines for Good Clinical Practice, and applicable regulatory requirements in China. Ethics approval was obtained from the medical ethics committee of Beijing Children\u2019s Hospital, Capital Medical University (Approval No. [2023]-Y-019-A), as well as by the institutional review boards of all participating centers prior to study initiation (Supplementary Table S1). Written informed consent was obtained from the parents or legal guardians of all participants, and assent was obtained from participants as required by local regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}